GondolaBio
Gondola Bio
Palo Alto, United States · Founded 2024 · $300.0M raised
- Headquarters
- Palo Alto, California
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- gondolabio.com
- Total Funding
- $300.0M
- Last Round
- $300.0M Series AAug 2024
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
GondolaBio is a clinical-stage biopharmaceutical company developing breakthrough therapeutics for patients living with genetic diseases. A sister company of BridgeBio Pharma, GondolaBio launched in 2024 with a decentralized approach to drug development. Its lead program PORT-77 is an oral small molecule ABCG2 inhibitor currently in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
Summary
GondolaBio is a Biotech company based in Palo Alto, United States, founded in 2024. It has raised $300.0M in total across 1 round, most recently a $300.0M Series A round in Aug 2024. Investors include Sanofi Ventures, Viking Global and Patient Square Capital.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Aug 2024
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/gondolabio"><img src="https://indexed.vc/api/badge/company/gondolabio" alt="GondolaBio on Indexed.vc" width="260" height="76" /></a>